These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11736971)

  • 1. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
    Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
    Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
    Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
    Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T
    Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
    Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
    Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
    Wang CS; Wu TL; Tsao KC; Sun CF
    Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients.
    Ishida H; Murata N; Hayashi Y; Tada M; Hashimoto D
    Surg Today; 2003; 33(12):885-92. PubMed ID: 14669077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
    Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
    Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study.
    Birgisson H; Nielsen HJ; Christensen IJ; Glimelius B; Brünner N
    Eur J Cancer; 2010 Dec; 46(18):3323-31. PubMed ID: 20619633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
    Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ
    Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
    Frederiksen C; Lomholt AF; Davis GJ; Dowell BL; Blankenstein MA; Christensen IJ; Brünner N; Nielsen HJ
    Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer: correlation with clinico-morphological factors].
    Korotkova EA; Gershteĭn ES; Prorokov VV; Kushlinskiĭ NE
    Vopr Onkol; 2009; 55(2):171-6. PubMed ID: 19514370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
    Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
    Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
    Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
    Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
    Hatate K; Yamashita K; Hirai K; Kumamoto H; Sato T; Ozawa H; Nakamura T; Onozato W; Kokuba Y; Ihara A; Watanabe M
    Oncol Rep; 2008 Oct; 20(4):737-43. PubMed ID: 18813812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
    Larsen MB; Stephens RW; Brünner N; Nielsen HJ; Engelholm LH; Christensen IJ; Stetler-Stevenson WG; Høyer-Hansen G
    Scand J Immunol; 2005 May; 61(5):449-60. PubMed ID: 15882437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.